Stocks like Pidilite Industries, Fino Payments Bank, Reliance Industries, and Modern Diagnostic & Research Centre will be in focus on January 7.

shorts/business/stocks-to-watch-today-titan-jubilant-foodworks-godrej-consumer-products-irb-infrastructure-trust-pidilite-fino-payments-bank-in-focus-on-7-january

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, and order wins, here’s a quick look at which stocks will be in focus in today's trade:

<a href="https://www.moneycontrol.com/markets/earnings/" target="_blank">Results Today</a>

Galaxy Agrico Exports, Mahesh Developers, Premier Energy and Infrastructure, and Siddheswari Garments will release quarterly earnings today.

<a href="https://www.moneycontrol.com/markets/earnings/" target="_blank">Quarterly Business Updates</a>

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/titancompany/TI01" target="_blank">Titan Company</a> Q3 (YoY)

Domestic business grows 38%

International business spikes 79%

Consumer business surges 40%

Watch business soars 13%

EyeCare business rises 16%

Emerging business increases 14%

Jewellery business zooms 41%

Company adds 54 new domestic stores &amp; 2 new international stores, taking total stores count to 3,433

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/jubilantfoodworks/JF04" target="_blank">Jubilant Foodworks</a> Q3 (YoY)

Consolidated revenue from operations grows 13.4% to Rs 2,438.7 crore

Domino’s India Like-for-like growth at 5%

Domino’s India opened 75 new stores, ending the quarter with 2,396 stores

<a href="https://www.moneycontrol.com/india/stockpricequote/personal-care/godrejconsumerproducts/GCP" target="_blank">Godrej Consumer Products</a> Q3 (YoY)

Demand conditions in India strengthens progressively in Q3

Company remains confident of gradual improvement in consumption over coming quarters, supported by falling inflation and lower GST rates

Standalone business to deliver double-digit revenue growth, with double-digit underlying volume growth

Home Care segment to deliver double-digit value growth on sustained consumer demand and effective in-market execution

Personal Care to record mid-single-digit value growth, driven by a marked recovery in soaps category

Standalone EBITDA margins to revert to the normative range, aided by favourable input costs, disciplined cost management, improved operating leverage

Indonesia continues to face pricing pressure, improvement expected in both revenue and profitability from FY27 onwards

GAUM (Godrej Africa, USA and Middle East) to deliver a strong performance, FY26 guidance of double-digit top and bottom-line growth reaffirmed

At consolidated level, company expects double-digit revenue growth in INR terms and double-digit EBITDA growth

<a href="https://www.moneycontrol.com/india/stockpricequote/construction-residentialcommercial-complexes/lodhadevelopers/MD03" target="_blank">Lodha Developers</a> Q3 (YoY)

Pre-sales grow 25% to Rs 5,620 crore Vs Rs 4,510 crore

Collections fall 17% to Rs 3,560 crore Vs Rs 4,290 crore

Company adds 5 projects with GDV of Rs 33,800 crore in MMR, NCR and Bengaluru

Stocks to Watch

<a href="https://www.moneycontrol.com/india/stockpricequote/banks-private-sector/yesbank/YB" target="_blank">Yes Bank</a>

The bank has received approval from the National Securities Depository (NSDL) for the transfer of its demat undertaking under the retail division to its subsidiary, Yes Securities (India).

<a href="https://www.moneycontrol.com/india/stockpricequote/infrastructure/irbinfrastructuretrust/IRBIT14806" target="_blank">IRB Infrastructure Trust</a>

The Trust has emerged as the selected bidder and has received a Letter of Award from the National Highways Authority of India (NHAI) for the project involving the tolling, operation, maintenance, and transfer of the Chandikhole–Bhadrak section of NH-16 in Odisha.

The Trust will pay an upfront bid concession fee of Rs 3,087 crore to NHAI for a revenue-linked concession period of 20 years.

<a href="https://www.moneycontrol.com/india/stockpricequote/diversified/indianenergyexchange/IEE" target="_blank">Indian Energy Exchange</a>

At this stage, the company said the matter is sub judice, and no order or direction has been passed by the Appellate Tribunal for Electricity (APTEL) on the CERC market coupling issue.

The hearing was scheduled on January 6 before APTEL in respect of the petition filed by the company challenging the Suo Motu order dated July 23, 2025, issued by the Central Electricity Regulatory Commission (CERC) pertaining to the implementation of market coupling.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/biocon/BL03" target="_blank">Biocon</a>

The company’s subsidiary, Biocon Biologics, will introduce three new oncology biosimilars at the JP Morgan Healthcare Conference in San Francisco, further strengthening its comprehensive cancer portfolio.

<a href="https://www.moneycontrol.com/india/stockpricequote/oil-drillingexploration/oilnaturalgascorporation/ONG" target="_blank">Oil and Natural Gas Corporation</a>

The senior management of ONGC, including Director (Technology &amp; Field Services) Vikram Saxena from Delhi, along with Crisis Management Team (CMT) experts, has assumed operational control of Well Mori-5 at Irusumanda, Malkipuram Mandal, following the incident at the site.

A gradual reduction in flame intensity and size is being witnessed.

<a href="https://www.moneycontrol.com/india/stockpricequote/chemicals/pidiliteindustries/PI11" target="_blank">Pidilite Industries</a>

The company’s subsidiary, Pidilite Ventures (PVPL), has transferred its entire shareholding in Pepperfry to TCC Concept (TCC) in a 100 percent share-swap deal, pursuant to the acquisition of shares of Pepperfry by TCC.

Accordingly, PVPL now holds a 2.20 percent shareholding in TCC. The promoters/promoter group of PVPL have no interest in TCC.

<a href="https://www.moneycontrol.com/india/stockpricequote/finance-others/finopaymentsbank/FPB" target="_blank">Fino Payments Bank</a>

The bank announced the implementation of a new next-generation Core Banking System as part of its ongoing digital transformation programme.

The migration of the Core Banking System to the new Finacle platform is planned from January 8 to January 10. During this period, all banking services will not be available.

<a href="https://www.moneycontrol.com/india/stockpricequote/refineries/relianceindustries/RI" target="_blank">Reliance Industries</a>

Reliance Industries strongly rejected claims of Russian oil imports to its Jamnagar refinery, stating that such news reports are “blatantly untrue” and are “tarnishing” its image.

The company informed the exchanges that there is no linkage between the movement in the price of its equity shares and reports on Russian oil imports.

Despite the company’s denial of purchasing any Russian oil for delivery in January, a news report was published by Bloomberg claiming that “three vessels laden with Russian oil are heading for Reliance Industries Limited’s Jamnagar refinery.”

Later, Bloomberg updated its report, clarifying that the Russian oil cargo earlier linked to Reliance was discharged elsewhere.

The company stated that there is no information that has not been announced to the stock exchanges and that it has made and will continue to make disclosures in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations and agreements with the stock exchanges.

Bulk Deals

<a href="https://www.moneycontrol.com/india/stockpricequote/chemicals/spebadhesives/SAL06" target="_blank">Speb Adhesives</a>

Venture capital firm Compact Structure Fund has bought 1.8 lakh shares (equivalent to 0.8 percent of the paid-up equity) in Speb Adhesives at Rs 55.86 per share for over Rs 1 crore.

Compact Structure Fund already held 19.66 lakh shares (an 8.75 percent stake) in Speb as of December 5, 2025.

<a href="https://www.moneycontrol.com/india/stockpricequote/trading/dhariwalcorp/DL04" target="_blank">Dhariwalcorp</a>

Greenx Wealth Multihorizons Opportunity Fund has picked up 61,800 shares (a 0.65 percent stake) in the wax and industrial chemicals trader at Rs 361 per share for Rs 2.23 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/computer-peripherals/epwindia/EIL05" target="_blank">EPW India</a>

Tiger Strategies Fund–I sold a further 60,000 shares in EPW at Rs 100.2 per share for Rs 60.12 lakh, after selling 1.41 lakh shares in the previous session. The fund held a 4.65 percent stake (5.34 lakh shares) in the company as of December 29, 2025.

SME Listing

Modern Diagnostic &amp; Research Centre

Stocks in F&amp;O ban

Sammaan Capital
SAIL

Disclaimer: MoneyControl is a part of the Network18 group. Network18 is controlled by Independent Media Trust, of which Reliance Industries is the sole beneficiary.

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

Stocks to Watch Today: Titan, Jubilant Foodworks, Godrej Consumer Products, IRB Infrastructure Trust, Pidilite, Fino Payments Bank in focus on 7 January

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, and order wins, here’s a quick look at which stocks will be in focus in today's trade:

Results Today

Galaxy Agrico Exports, Mahesh Developers, Premier Energy and Infrastructure, and Siddheswari Garments will release quarterly earnings today.

Quarterly Business Updates

Titan Company Q3 (YoY)

Domestic business grows 38%

International business spikes 79%

Consumer business surges 40%

Watch business soars 13%

EyeCare business rises 16%

Emerging business increases 14%

Jewellery business zooms 41%

Company adds 54 new domestic stores &amp;amp; 2 new international stores, taking total stores count to 3,433

Jubilant Foodworks Q3 (YoY)

Consolidated revenue from operations grows 13.4% to Rs 2,438.7 crore

Domino’s India Like-for-like growth at 5%

Domino’s India opened 75 new stores, ending the quarter with 2,396 stores

Godrej Consumer Products Q3 (YoY)

Demand conditions in India strengthens progressively in Q3

Company remains confident of gradual improvement in consumption over coming quarters, supported by falling inflation and lower GST rates

Standalone business to deliver double-digit revenue growth, with double-digit underlying volume growth

Home Care segment to deliver double-digit value growth on sustained consumer demand and effective in-market execution

Personal Care to record mid-single-digit value growth, driven by a marked recovery in soaps category

Standalone EBITDA margins to revert to the normative range, aided by favourable input costs, disciplined cost management, improved operating leverage

Indonesia continues to face pricing pressure, improvement expected in both revenue and profitability from FY27 onwards

GAUM (Godrej Africa, USA and Middle East) to deliver a strong performance, FY26 guidance of double-digit top and bottom-line growth reaffirmed

At consolidated level, company expects double-digit revenue growth in INR terms and double-digit EBITDA growth

Lodha Developers Q3 (YoY)

Pre-sales grow 25% to Rs 5,620 crore Vs Rs 4,510 crore

Collections fall 17% to Rs 3,560 crore Vs Rs 4,290 crore

Company adds 5 projects with GDV of Rs 33,800 crore in MMR, NCR and Bengaluru

Stocks to Watch

Yes Bank

The bank has received approval from the National Securities Depository (NSDL) for the transfer of its demat undertaking under the retail division to its subsidiary, Yes Securities (India).

IRB Infrastructure Trust

The Trust has emerged as the selected bidder and has received a Letter of Award from the National Highways Authority of India (NHAI) for the project involving the tolling, operation, maintenance, and transfer of the Chandikhole–Bhadrak section of NH-16 in Odisha.

The Trust will pay an upfront bid concession fee of Rs 3,087 crore to NHAI for a revenue-linked concession period of 20 years.

Indian Energy Exchange

At this stage, the company said the matter is sub judice, and no order or direction has been passed by the Appellate Tribunal for Electricity (APTEL) on the CERC market coupling issue.

The hearing was scheduled on January 6 before APTEL in respect of the petition filed by the company challenging the Suo Motu order dated July 23, 2025, issued by the Central Electricity Regulatory Commission (CERC) pertaining to the implementation of market coupling.

Biocon

The company’s subsidiary, Biocon Biologics, will introduce three new oncology biosimilars at the JP Morgan Healthcare Conference in San Francisco, further strengthening its comprehensive cancer portfolio.

Oil and Natural Gas Corporation

The senior management of ONGC, including Director (Technology &amp;amp; Field Services) Vikram Saxena from Delhi, along with Crisis Management Team (CMT) experts, has assumed operational control of Well Mori-5 at Irusumanda, Malkipuram Mandal, following the incident at the site.

A gradual reduction in flame intensity and size is being witnessed.

Pidilite Industries

The company’s subsidiary, Pidilite Ventures (PVPL), has transferred its entire shareholding in Pepperfry to TCC Concept (TCC) in a 100 percent share-swap deal, pursuant to the acquisition of shares of Pepperfry by TCC.

Accordingly, PVPL now holds a 2.20 percent shareholding in TCC. The promoters/promoter group of PVPL have no interest in TCC.

Fino Payments Bank

The bank announced the implementation of a new next-generation Core Banking System as part of its ongoing digital transformation programme.

The migration of the Core Banking System to the new Finacle platform is planned from January 8 to January 10. During this period, all banking services will not be available.

Reliance Industries

Reliance Industries strongly rejected claims of Russian oil imports to its Jamnagar refinery, stating that such news reports are “blatantly untrue” and are “tarnishing” its image.

The company informed the exchanges that there is no linkage between the movement in the price of its equity shares and reports on Russian oil imports.

Despite the company’s denial of purchasing any Russian oil for delivery in January, a news report was published by Bloomberg claiming that “three vessels laden with Russian oil are heading for Reliance Industries Limited’s Jamnagar refinery.”

Later, Bloomberg updated its report, clarifying that the Russian oil cargo earlier linked to Reliance was discharged elsewhere.

The company stated that there is no information that has not been announced to the stock exchanges and that it has made and will continue to make disclosures in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations and agreements with the stock exchanges.

Bulk Deals

Speb Adhesives

Venture capital firm Compact Structure Fund has bought 1.8 lakh shares (equivalent to 0.8 percent of the paid-up equity) in Speb Adhesives at Rs 55.86 per share for over Rs 1 crore.

Compact Structure Fund already held 19.66 lakh shares (an 8.75 percent stake) in Speb as of December 5, 2025.

Dhariwalcorp

Greenx Wealth Multihorizons Opportunity Fund has picked up 61,800 shares (a 0.65 percent stake) in the wax and industrial chemicals trader at Rs 361 per share for Rs 2.23 crore.

EPW India

Tiger Strategies Fund–I sold a further 60,000 shares in EPW at Rs 100.2 per share for Rs 60.12 lakh, after selling 1.41 lakh shares in the previous session. The fund held a 4.65 percent stake (5.34 lakh shares) in the company as of December 29, 2025.

SME Listing

Modern Diagnostic &amp;amp; Research Centre

Stocks in F&amp;amp;O ban

Sammaan Capital
SAIL

Disclaimer: MoneyControl is a part of the Network18 group. Network18 is controlled by Independent Media Trust, of which Reliance Industries is the sole beneficiary.

Compact Structure Fund already held 19.66 lakh shares (8.75 percent stake) in Speb Adhesives as of December 5, 2025.

shorts/business/compact-structure-fund-acquires-additional-0-8-stake-in-speb-adhesives

Venture capital firm Compact Structure Fund has acquired additional 0.8 percent equity stake in Speb Adhesives, the synthetic rubber-based adhesives maker, via open market transactions on January 6.

<a href="https://www.moneycontrol.com/india/stockpricequote/chemicals/spebadhesives/SAL06">Speb Adhesives</a> shares rallied 3.41 percent to Rs 56.10 amid high volumes on the NSE, extending uptrend for second consecutive session. In previous session, the stock surged over 7 percent.

Compact Structure Fund has bought 1.8 lakh shares (equivalent to 0.8 percent of paid-up equity) in Speb Adhesives at Rs 55.86 per share for over Rs 1 crore.

Compact Structure Fund already held 19.66 lakh shares (8.75 percent stake) in Speb as of December 5, 2025.

<a href="https://www.moneycontrol.com/india/stockpricequote/trading/dhariwalcorp/DL04">Dhariwalcorp</a> shares also gained 3.62 percent to finish at Rs 361.75 after falling over 5 percent in previous two trading sessions. Greenx Wealth Multihorizons Opportunity Fund has picked up 61,800 shares (0.65 percent stake) in the wax and industrial chemicals trader at Rs 361 per share for Rs 2.23 crore.

The brisk action continued in laptop refurbishing company <a href="https://www.moneycontrol.com/india/stockpricequote/computer-peripherals/epwindia/EIL05">EPW India</a> shares, extending downtrend for fourth consecutive session and declining 2.21 percent to Rs 101.7 on Tuesday.

Tiger Strategies Fund -I sold further 60,000 shares in EPW at Rs 100.2 per share for Rs 60.12 lakh, after selling 1.41 lakh shares in previous session. The fund was holding 4.65 percent stake (5.34 lakh shares) in the company as of December 29, 2025.

<img class="alignnone size-full wp-image-13760208 aligncenter" src="https://images.moneycontrol.com/static-mcnews/2026/01/20260106190924_Image2106012026.jpg" alt="Image2106012026" width="1944" height="3953" />

Compact Structure Fund acquires additional 0.8% stake in Speb Adhesives

Venture capital firm Compact Structure Fund has acquired additional 0.8 percent equity stake in Speb Adhesives, the synthetic rubber-based adhesives maker, via open market transactions on January 6.

Speb Adhesives shares rallied 3.41 percent to Rs 56.10 amid high volumes on the NSE, extending uptrend for second consecutive session. In previous session, the stock surged over 7 percent.

Compact Structure Fund has bought 1.8 lakh shares (equivalent to 0.8 percent of paid-up equity) in Speb Adhesives at Rs 55.86 per share for over Rs 1 crore.

Compact Structure Fund already held 19.66 lakh shares (8.75 percent stake) in Speb as of December 5, 2025.

Dhariwalcorp shares also gained 3.62 percent to finish at Rs 361.75 after falling over 5 percent in previous two trading sessions. Greenx Wealth Multihorizons Opportunity Fund has picked up 61,800 shares (0.65 percent stake) in the wax and industrial chemicals trader at Rs 361 per share for Rs 2.23 crore.

The brisk action continued in laptop refurbishing company EPW India shares, extending downtrend for fourth consecutive session and declining 2.21 percent to Rs 101.7 on Tuesday.

Tiger Strategies Fund -I sold further 60,000 shares in EPW at Rs 100.2 per share for Rs 60.12 lakh, after selling 1.41 lakh shares in previous session. The fund was holding 4.65 percent stake (5.34 lakh shares) in the company as of December 29, 2025.

Pharma stocks surged as brokerages issued positive notes for key companies, Nifty Pharma index rose 1.7 percent; Divi's Labs shares jumped over 4.5 percent, HDFC Securities sees India's CRDMO market share rising to 4.7 percent by 2029

* Pharma stocks surged as brokerages issued positive notes for key companies
* Nifty Pharma index rose 1.7 percent; Divi's Labs shares jumped over 4.5 percent
* HDFC Securities sees India's CRDMO market share rising to 4.7 percent by 2029

Pharma stocks surged, pushing the Nifty Pharma index up 1.7%, after positive brokerage notes and strong December growth. HDFC Securities sees rising R&D outsourcing boosting Indian drug makers, with Divi’s Labs named a top pick by Citi for future growth.

shorts/business/divi-s-labs-lupin-other-pharma-stocks-rise-up-to-4-here-s-why-hdfc-securities-says-sector-looks-attractive

* Pharma stocks surged as brokerages issued positive notes for key companies
* Nifty Pharma index rose 1.7 percent; Divi's Labs shares jumped over 4.5 percent
* HDFC Securities sees India's CRDMO market share rising to 4.7 percent by 2029

The shares of pharma companies jumped on January 6 as brokerages issued positive notes for several of the key players, as well as the entire sector.

The sharp rise in the share prices pushed the <a href="https://www.moneycontrol.com/indian-indices/nifty-pharma-41.html">Nifty Pharma</a> index nearly 1.7 percent to 23,126.85 on Tuesday.

“Pharma stocks advanced due to the consistent growth reported by the Indian Pharmaceutical Market (IPM) for December,” said Vinod Nair, Head of Research, Geojit Investments. Bajaj Broking meanwhile attributed the sharp rise in the share prices to selective buying.

HDFC Securities began coverage on Indian contract drug makers Divi’s Labs, <a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticalsdrugs/anthembiosciences/ABL07">Anthem Biosciences</a>, Sai Life Sciences, <a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/lauruslabs/LL05">Laurus Labs</a> and Piramal Pharma. The brokerage sees rising research &amp; development outsourcing boosting Indian contract drug makers that have expanded capabilities to cover various stages of drug development.

India's share in global contract research, development, and manufacturing organisations (CRDMO) market will likely rise to 4.7 percent by 2029 from 3.8 percent in 2024, "making it an attractive sector", it added.

HDFC Securities further said that low labour costs will act as an advantage as companies reduce China dependence. It expects revenue CAGR to accelerate to 15 percent in FY25-28 as against 9 percent in FY23-25, with EBITDA CAGR at 22 percent as against 12 percent.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/divislaboratories/DL03">Divi's Laboratories</a> shares jumped over 4.5 percent to close at Rs 6,651 apiece. Citi has called the stock its “top pick” in India’s pharma sector, stating that 2026 can be an inflection year for the company. It added that Divi’s has strong pipeline catalysts over the next 12 months and the generic segment is expected to witness a recovery. Citi expects the company’s revenue to expand by three times, and EBITDA to rise by four times over FY25-FY30.

IPCA Laboratories and Lupin shares gained 4 percent, Aurobindo Pharma, Mankind Pharma, Glenmark Pharma and JB Chemicals &amp; Pharmaceuticals shares rose more than 2 percent each. Torrent Pharmaceuticals, Alkem Laboratories and Sun Pharmaceutical Industries shares gained nearly 2 percent each.

Wockhardt, Laurus Labs and Zydus Lifesciences shares gained more than 1 percent each, while Abbott India, Piramal Pharma and Cipla shares rose nearly 1 percent each. Bucking the trend, Ajanta Pharma shares fell 2.5 percent each, while Biocon and Gland Pharma shares fell 1 percent each.

(With inputs from Reuters)

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Divi's Labs, Lupin, other pharma stocks rise up to 4%; here's why HDFC Securities says sector looks 'attractive'

The shares of pharma companies jumped on January 6 as brokerages issued positive notes for several of the key players, as well as the entire sector.

The sharp rise in the share prices pushed the Nifty Pharma index nearly 1.7 percent to 23,126.85 on Tuesday.

“Pharma stocks advanced due to the consistent growth reported by the Indian Pharmaceutical Market (IPM) for December,” said Vinod Nair, Head of Research, Geojit Investments. Bajaj Broking meanwhile attributed the sharp rise in the share prices to selective buying.

HDFC Securities began coverage on Indian contract drug makers Divi’s Labs, Anthem Biosciences, Sai Life Sciences, Laurus Labs and Piramal Pharma. The brokerage sees rising research &amp;amp; development outsourcing boosting Indian contract drug makers that have expanded capabilities to cover various stages of drug development.

India's share in global contract research, development, and manufacturing organisations (CRDMO) market will likely rise to 4.7 percent by 2029 from 3.8 percent in 2024, &quot;making it an attractive sector&quot;, it added.

HDFC Securities further said that low labour costs will act as an advantage as companies reduce China dependence. It expects revenue CAGR to accelerate to 15 percent in FY25-28 as against 9 percent in FY23-25, with EBITDA CAGR at 22 percent as against 12 percent.

Divi's Laboratories shares jumped over 4.5 percent to close at Rs 6,651 apiece. Citi has called the stock its “top pick” in India’s pharma sector, stating that 2026 can be an inflection year for the company. It added that Divi’s has strong pipeline catalysts over the next 12 months and the generic segment is expected to witness a recovery. Citi expects the company’s revenue to expand by three times, and EBITDA to rise by four times over FY25-FY30.

IPCA Laboratories and Lupin shares gained 4 percent, Aurobindo Pharma, Mankind Pharma, Glenmark Pharma and JB Chemicals &amp;amp; Pharmaceuticals shares rose more than 2 percent each. Torrent Pharmaceuticals, Alkem Laboratories and Sun Pharmaceutical Industries shares gained nearly 2 percent each.

Wockhardt, Laurus Labs and Zydus Lifesciences shares gained more than 1 percent each, while Abbott India, Piramal Pharma and Cipla shares rose nearly 1 percent each. Bucking the trend, Ajanta Pharma shares fell 2.5 percent each, while Biocon and Gland Pharma shares fell 1 percent each.

(With inputs from Reuters)

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Shares of electronics manufacturing services (EMS) companies <a href="https://www.moneycontrol.com/india/stockpricequote/electronics-components/kaynestechnologyindia/KTI">Kaynes Technology India</a> and <a href="https://www.moneycontrol.com/india/stockpricequote/electricals/dixontechnologies/DT07">Dixon Technologies (India)</a> fell by up to 5.5 percent on Tuesday amid profit booking, even as brokerage firm Jefferies maintained a positive outlook on the sector through FY28.

Shares of Kaynes Technology declined 5.37 percent to close at Rs 3,783 apiece on the National Stock Exchange (NSE), while Dixon Technologies settled 3.11 percent lower at Rs 11,676.

Amber Enterprises India ended flat at Rs 6,710 pershare, while Syrma SGS Technology closed marginally higher at Rs 752.10, up 0.25 percent.

The decline in select stocks came despite Jefferies projecting strong growth for Indian EMS companies over the medium term.

In a note, Jefferies said Indian electronics manufacturers are expected to deliver a compound annual growth rate (CAGR) of 44 percent in earnings per share between FY25 and FY28, driven by execution.

The brokerage said the government's production-linked incentive (PLI) scheme for components has supported growth in the segment and added that it prefers Indian component manufacturers over original equipment manufacturers in 2026.

Jefferies estimates total capital expenditure of Amber Enterprises, Syrma SGS Technology, Kaynes Technology India and Dixon Technologies at around Rs 100 billion between FY26 and FY28, with return on capital employed (RoCE) seen in the range of 15–17 percent.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

A financial journalist with over 10 years of experience, specialising in tracking stock market movements and fundamental developments that impact investors and the broader economy. A keen observer of global financial markets, I regularly engage with leading market voices to write stories. At Moneycontrol, I focus on decoding market trends, policy shifts and economic changes, driven by a constant passion to learn, analyse, and share knowledge with my readers.

Kaynes Tech, Dixon fall up to 5.5% even as Jefferies expects strong growth from EMS firms through FY28

Shares of electronics manufacturing services (EMS) companies Kaynes Technology India and Dixon Technologies (India) fell by up to 5.5 percent on Tuesday amid profit booking, even as brokerage firm Jefferies maintained a positive outlook on the sector through FY28.

Shares of Kaynes Technology declined 5.37 percent to close at Rs 3,783 apiece on the National Stock Exchange (NSE), while Dixon Technologies settled 3.11 percent lower at Rs 11,676.

Amber Enterprises India ended flat at Rs 6,710 pershare, while Syrma SGS Technology closed marginally higher at Rs 752.10, up 0.25 percent.

The decline in select stocks came despite Jefferies projecting strong growth for Indian EMS companies over the medium term.

In a note, Jefferies said Indian electronics manufacturers are expected to deliver a compound annual growth rate (CAGR) of 44 percent in earnings per share between FY25 and FY28, driven by execution.

The brokerage said the government's production-linked incentive (PLI) scheme for components has supported growth in the segment and added that it prefers Indian component manufacturers over original equipment manufacturers in 2026.

Jefferies estimates total capital expenditure of Amber Enterprises, Syrma SGS Technology, Kaynes Technology India and Dixon Technologies at around Rs 100 billion between FY26 and FY28, with return on capital employed (RoCE) seen in the range of 15–17 percent.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

ITC shares fell over 15 percent in four days after new excise duty on cigarettes, Stock hit a 52-week low, erasing Rs 82,000 crore in market cap, Analysts advise caution as bearish momentum and technical weakness persist

* ITC shares fell over 15 percent in four days after new excise duty on cigarettes
* Stock hit a 52-week low, erasing Rs 82,000 crore in market cap
* Analysts advise caution as bearish momentum and technical weakness persist

ITC shares fell over 15% in four days, hitting a 52-week low after a new excise duty on cigarettes was imposed. Analysts cite ongoing bearish momentum, technical weakness, and advise caution, with key support at Rs 310 and resistance at Rs 380-390.

shorts/business/itc-falls-2-extend-2026-losses-to-15-has-the-dividend-stock-bottomed-out-here-s-what-analysts-say

* ITC shares fell over 15 percent in four days after new excise duty on cigarettes
* Stock hit a 52-week low, erasing Rs 82,000 crore in market cap
* Analysts advise caution as bearish momentum and technical weakness persist

The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/diversified/itc/ITC">ITC</a> dropped more than 2 percent on January 6, extending losses to 15 percent in four sessions after government imposed new excise duty on cigarettes. Analysts noted that the bearish momentum continues to prevail, while listing out key levels to watch out for possible recovery.

The shares of the hotels-to-cigarettes conglomerate dropped to a fresh 52-week low of Rs 337.75 apiece. This takes the total market cap erosion to Rs 82,000 crore in just four days. The stock later recovered some losses to close at Rs 343.25 apiece.

ITC is widely-regarded as a safe stock to hold considering its dividend-paying history. In FY25, ITC declared and paid a total dividend of Rs 14.35 per share. As of January 6, 2026, the company's dividend yield is approximately 4.10 percent.
<h3>Why are ITC shares falling?</h3>
The Parliament in December approved the Central Excise (Amendment) Bill, 2025, clearing the way for a sharp increase in duties on cigarettes and other tobacco products. It replaces a temporary levy on cigarettes and tobacco products.

The excise duty would be imposed on cigarettes in addition to a 40 percent GST, according to an order issued late on Wednesday. The finance ministry notified that an excise duty of Rs 2,050–8,500 per 1,000 sticks, depending on cigarette length, will take effect from February 1.

The duty translates into a 22-28 percent increase in overall costs for 75-85 mm cigarettes, analysts at ICICI Securities said. "Cigarettes longer than 75 mm account for roughly 16% of ITC's volumes and are likely to see price increases of 2–3 rupees per stick as a result of the levy," they said.
<h3>ITC technical view:</h3>
The stock is continuing to trade under pressure as it is kept below the crucial moving averages, with bearish momentum prevailing, said Siddharth Maurya, Founder &amp; Managing Director, Vibhavangal Anukulakara.

The analyst added that the initial level of support is seen around Rs 328, while the resistance can be noted at Rs 388-390. "A close above the resistance mark might trigger the recovery phase; however, a close below Rs 328 might result in intensification of the negative trend,” he further said.

ITC's collapse following the 40 percent cigarette tax hike has triggered one of the most violent single-day liquidations in recent memory, with volumes surging to 30 times the daily average - a classic capitulation signature that often marks exhaustion bottoms rather than the beginning of sustained declines, said Darshan Rathod, Director and COO of Multyfi.
<h3>'Technical damage is severe yet...'</h3>
"The technical damage is severe yet paradoxically constructive for contrarians. The breach of ₹375-380 multi-year support and subsequent plunge to ₹342 has pushed the stock 15% below its 200-day SMA. On the monthly timeframe, this represents the deepest oversold condition since the COVID crash, with the stock now trading at a 15% monthly decline… The derivatives landscape tells a nuanced story. While Call writing at ₹350 reflects near-term bearishness, the Put/Call ratio of 0.61 and total Put OI of 7.71 crore versus Call OI of 12.54 crore suggests the street may be overly positioned for downside. The heavy Put accumulation at ₹340-330 strikes indicates smart money establishing safety nets,” he added.

Rathod explained that in the near-term, Rs 340 becomes a key level to watch out for. Reclaiming Rs 360 with normalizing volumes would confirm stabilization, while sustained trade below Rs 335 risks extension toward Rs 310-300, though genuine trend reversal requires reconquest of Rs 400, he said.
<h3>'Downside momentum to continue, avoid fresh entries':</h3>
Drumil Vithlani, Technical Research Analyst at Bonanza, said that the stock is clearly showing strong bearish sentiment. “The stock is now in a downtrend and is trading below all major EMAs of 20, 50, 100, and 200, confirming weakness on the weekly timeframe. The RSI stands at 22.96, indicating an oversold zone; however, its 14-day RSI average is near 42.8, suggesting that any short-term cool-off in RSI may not translate into a sustainable reversal,” he said.

The analyst expects the downside momentum to continue, and advised investors to avoid fresh entries. “The earlier support at 380 now acts as a strong resistance zone, while the next major support is placed near the 310 level,” he said.

Macquarie has downgraded the stock to 'Neutral' from 'Buy', and slashed its target price by 34 percent to Rs 330 apiece, NDTV Profit reported. The latest target price implies a downside potential of around 6 percent from the stock's previous closing price.

ITC’s trend has weakened meaningfully following a sharp breakdown from the crucial support zone around the Rs 400 level, said Ajit Mishra – SVP, Research, Religare Broking. The stock has decisively slipped below the 100-week moving average, with a strong bearish candle accompanied by a spike in volumes, indicating distribution rather than routine profit booking, he added.

"Momentum indicators have deteriorated, as the RSI has drifted towards the 50 zone and the stochastic oscillator has entered a bearish crossover, pointing to further downside risk. Immediate support is placed in the ₹330–340 zone, which remains a critical medium-term support area. A sustained break below this band could open the door for a deeper corrective move towards the ₹300 mark. On the upside, any recovery attempt is likely to face initial resistance near ₹360, followed by a major hurdle around ₹390. Participants are advised to avoid aggressive positioning at current levels and wait for clear signs of consolidation or stabilization," he further said.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

ITC falls 2%, extends 2026 losses to 15%: Has the 'dividend' stock bottomed out? Here's what analysts say

The shares of ITC dropped more than 2 percent on January 6, extending losses to 15 percent in four sessions after government imposed new excise duty on cigarettes. Analysts noted that the bearish momentum continues to prevail, while listing out key levels to watch out for possible recovery.

The shares of the hotels-to-cigarettes conglomerate dropped to a fresh 52-week low of Rs 337.75 apiece. This takes the total market cap erosion to Rs 82,000 crore in just four days. The stock later recovered some losses to close at Rs 343.25 apiece.

ITC is widely-regarded as a safe stock to hold considering its dividend-paying history. In FY25, ITC declared and paid a total dividend of Rs 14.35 per share. As of January 6, 2026, the company's dividend yield is approximately 4.10 percent.
Why are ITC shares falling?
The Parliament in December approved the Central Excise (Amendment) Bill, 2025, clearing the way for a sharp increase in duties on cigarettes and other tobacco products. It replaces a temporary levy on cigarettes and tobacco products.

The excise duty would be imposed on cigarettes in addition to a 40 percent GST, according to an order issued late on Wednesday. The finance ministry notified that an excise duty of Rs 2,050–8,500 per 1,000 sticks, depending on cigarette length, will take effect from February 1.

The duty translates into a 22-28 percent increase in overall costs for 75-85 mm cigarettes, analysts at ICICI Securities said. &quot;Cigarettes longer than 75 mm account for roughly 16% of ITC's volumes and are likely to see price increases of 2–3 rupees per stick as a result of the levy,&quot; they said.
ITC technical view:
The stock is continuing to trade under pressure as it is kept below the crucial moving averages, with bearish momentum prevailing, said Siddharth Maurya, Founder &amp;amp; Managing Director, Vibhavangal Anukulakara.

The analyst added that the initial level of support is seen around Rs 328, while the resistance can be noted at Rs 388-390. &quot;A close above the resistance mark might trigger the recovery phase; however, a close below Rs 328 might result in intensification of the negative trend,” he further said.

ITC's collapse following the 40 percent cigarette tax hike has triggered one of the most violent single-day liquidations in recent memory, with volumes surging to 30 times the daily average - a classic capitulation signature that often marks exhaustion bottoms rather than the beginning of sustained declines, said Darshan Rathod, Director and COO of Multyfi.
'Technical damage is severe yet...'
&quot;The technical damage is severe yet paradoxically constructive for contrarians. The breach of ₹375-380 multi-year support and subsequent plunge to ₹342 has pushed the stock 15% below its 200-day SMA. On the monthly timeframe, this represents the deepest oversold condition since the COVID crash, with the stock now trading at a 15% monthly decline… The derivatives landscape tells a nuanced story. While Call writing at ₹350 reflects near-term bearishness, the Put/Call ratio of 0.61 and total Put OI of 7.71 crore versus Call OI of 12.54 crore suggests the street may be overly positioned for downside. The heavy Put accumulation at ₹340-330 strikes indicates smart money establishing safety nets,” he added.

Rathod explained that in the near-term, Rs 340 becomes a key level to watch out for. Reclaiming Rs 360 with normalizing volumes would confirm stabilization, while sustained trade below Rs 335 risks extension toward Rs 310-300, though genuine trend reversal requires reconquest of Rs 400, he said.
'Downside momentum to continue, avoid fresh entries':
Drumil Vithlani, Technical Research Analyst at Bonanza, said that the stock is clearly showing strong bearish sentiment. “The stock is now in a downtrend and is trading below all major EMAs of 20, 50, 100, and 200, confirming weakness on the weekly timeframe. The RSI stands at 22.96, indicating an oversold zone; however, its 14-day RSI average is near 42.8, suggesting that any short-term cool-off in RSI may not translate into a sustainable reversal,” he said.

The analyst expects the downside momentum to continue, and advised investors to avoid fresh entries. “The earlier support at 380 now acts as a strong resistance zone, while the next major support is placed near the 310 level,” he said.

Macquarie has downgraded the stock to 'Neutral' from 'Buy', and slashed its target price by 34 percent to Rs 330 apiece, NDTV Profit reported. The latest target price implies a downside potential of around 6 percent from the stock's previous closing price.

ITC’s trend has weakened meaningfully following a sharp breakdown from the crucial support zone around the Rs 400 level, said Ajit Mishra – SVP, Research, Religare Broking. The stock has decisively slipped below the 100-week moving average, with a strong bearish candle accompanied by a spike in volumes, indicating distribution rather than routine profit booking, he added.

&quot;Momentum indicators have deteriorated, as the RSI has drifted towards the 50 zone and the stochastic oscillator has entered a bearish crossover, pointing to further downside risk. Immediate support is placed in the ₹330–340 zone, which remains a critical medium-term support area. A sustained break below this band could open the door for a deeper corrective move towards the ₹300 mark. On the upside, any recovery attempt is likely to face initial resistance near ₹360, followed by a major hurdle around ₹390. Participants are advised to avoid aggressive positioning at current levels and wait for clear signs of consolidation or stabilization,&quot; he further said.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Indices	Price	Chg%
Nifty Capital Market	4,707.85	0.41
Nifty India Defence	7,922.25	-0.30
Nifty 50	26,178.70	-0.27
Nifty Bank	60,118.40	0.12
Nifty Midcap 100	61,148.55	-0.19
Nifty Next 50	70,602.10	0.27
Nifty 100	26,808.75	-0.18
Nifty 200	14,615.75	-0.19

sector Analysis
Check Sector Performance, Sector Classification, Sector Earnings, Sector Growth and more to make better informed decisions.

sector Performance

All Sectors

Sectoral Indices

Stock News

Stocks to Watch Today: Titan, Jubilant Foodworks, Godrej Consumer Products, IRB Infrastructure Trust, Pidilite, Fino Payments Bank in focus on 7 January

Compact Structure Fund acquires additional 0.8% stake in Speb Adhesives

Divi's Labs, Lupin, other pharma stocks rise up to 4%; here's why HDFC Securities says sector looks 'attractive'

Kaynes Tech, Dixon fall up to 5.5% even as Jefferies expects strong growth from EMS firms through FY28

ITC falls 2%, extends 2026 losses to 15%: Has the 'dividend' stock bottomed out? Here's what analysts say

sector AnalysisCheck Sector Performance, Sector Classification, Sector Earnings, Sector Growth and more to make better informed decisions.

sector Performance

All Sectors

Sectoral Indices

Stock News

Stocks to Watch Today: Titan, Jubilant Foodworks, Godrej Consumer Products, IRB Infrastructure Trust, Pidilite, Fino Payments Bank in focus on 7 January

Compact Structure Fund acquires additional 0.8% stake in Speb Adhesives

Divi's Labs, Lupin, other pharma stocks rise up to 4%; here's why HDFC Securities says sector looks 'attractive'

Kaynes Tech, Dixon fall up to 5.5% even as Jefferies expects strong growth from EMS firms through FY28

ITC falls 2%, extends 2026 losses to 15%: Has the 'dividend' stock bottomed out? Here's what analysts say

sector Analysis
Check Sector Performance, Sector Classification, Sector Earnings, Sector Growth and more to make better informed decisions.